An interventional study of Trans-resveratrol, 1000 mg daily for 90 days and Placebo in Coronary Artery Disease (CAD), Menopause and Hormones, sponsored by InCor Heart Institute. Recruiting at 1 site in Brazil. Open to female participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by InCor Heart Institute · Not applicable, Interventional, and Prevention
Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.
Atherosclerotic coronary artery disease (CAD) is the leading cause of mortality among women in developed regions of Brazil. Diets rich in fruits and vegetables, which are sources of phenolic compounds, have been associated with a lower incidence of CAD, possibly due to their beneficial effects on vascular health. Resveratrol, a phenolic compound of the flavonoid group, is notable for its antioxidant properties, contributing to lipoprotein metabolism, production of endothelial vasodilator substances, and reduction of platelet aggregation.
Sirtuin-1 and sirtuin-3 play crucial roles in metabolic regulation in response to nutritional stimuli, such as caloric restriction and phenolic compound intake, and are also involved in hormonal modulation. However, the impact of resveratrol supplementation on serum estrogen and sirtuin levels has not yet been fully elucidated.
The primary objective of this study is to investigate the effects of resveratrol on serum concentrations of estradiol and estrone, gene expression of total estrogen receptors alpha and beta, and gene expression of sirtuins 1 and 3, in postmenopausal women with CAD undergoing resveratrol supplementation.
This is a randomized, double-blind, placebo-controlled clinical trial with a duration of 90 days, involving 80 postmenopausal women with CAD, allocated into two groups:
Group 1 (n=40): supplemented with trans-resveratrol, 1000 mg/day. Group 2 (n=40): placebo control. Clinical, nutritional, and laboratory assessments will be performed at baseline and at 90 days. Additional clinical nutritional assessments will be performed at 30 and 60 days from study initiation.
This investigation is expected to contribute to the understanding of the molecular mechanisms involved in the interaction between resveratrol and hormonal and biochemical markers, providing evidence to support more effective therapeutic strategies for postmenopausal women with chronic coronary disease.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's planned enrollment of 80 is below the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →InCor Heart Institute is the lead sponsor of 27 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Trans-resveratrol, 1000mg daily for 90 days.
Dietary Supplement: Trans-resveratrol, 1000 mg daily for 90 days
Starch, 1000mg daily for 90 days.
Other: Placebo
Trans-resveratrol, 1000 mg daily for 90 days
Also known as: Resveratrol
Starch, 1000 mg daily for 90 days
1. Sirtuin-1 and sirtuin-3
Serum concentrations and gene expression
Time frame: 90 days
Estradiol
Serum concentrations
Time frame: 90 days
Estrone
Serum concentrations
Time frame: 90 days
SHBG
Serum concentrations
Time frame: 90 days
Estrogen receptor alpha
Gene expression
Time frame: 90 days
Cardiometabolic risk factors
Lipid and glucometabolic profiles
Time frame: 90 days
BMI
kg/m²
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InCor Heart Institute